يعرض 1 - 10 نتائج من 42 نتيجة بحث عن '"Nishikawa, Reid A."', وقت الاستعلام: 1.00s تنقيح النتائج
  1. 1
    دورية أكاديمية
  2. 2
    كتاب

    المصدر: Outpatient Nutrition Care: GI, Metabolic and Home Nutrition Support ; page 311-321 ; ISBN 9780429322570

  3. 3
    دورية أكاديمية

    وصف الملف: application/pdf

    العلاقة: Ryder, Marcia, Robert A Gunther, Reid A Nishikawa, Marc Stranz, Britt M Meyer, Taylor A Spangler, Albert E Parker, and Charles Sylvia. “Investigation of the Role of Infusate Properties Related to Midline Catheter Failure in an Ovine Model.” American Journal of Health-System Pharmacy 77, no. 16 (July 24, 2020): 1336–1346. doi:10.1093/ajhp/zxaa175.; https://scholarworks.montana.edu/xmlui/handle/1/16428Test

  4. 4
    دورية أكاديمية
  5. 5
    دورية أكاديمية
  6. 6
    دورية أكاديمية

    وصف الملف: application/pdf

    العلاقة: Worthington, Patricia; Gura, Kathleen M.; Kraft, Michael D.; Nishikawa, Reid; Guenter, Peggi; Sacks, Gordon S. (2021). "Update on the Use of Filters for Parenteral Nutrition: An ASPEN Position Paper." Nutrition in Clinical Practice 36(1): 29-39.; https://hdl.handle.net/2027.42/166352Test; Nutrition in Clinical Practice; Krishna A, Rice M, Kester T, Waters M, Wilson T. Particulate study on NeoProfen, a neonatal injectable product. PDA J Pharm Sci Technol. 2016; 70 ( 1 ): 76 ‐ 92.; Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of medications with 3‐in‐1 parenteral nutrition admixtures. JPEN J Parenter Enteral Nutr. 1999; 23 ( 2 ): 67 ‐ 74.; Lehr H‐A, Brunner J, Rangoonwala R, Kirkpatrick CJ. Particulate matter contamination of intravenous antibiotics aggravates loss of functional capillary density in postischemic striated muscle. Am J Respir Crit Care Med. 2002; 165 ( 4 ): 514 ‐ 520.; Perez M, Decaudin B, Maiguy‐Foinard A, et al. Dynamic image analysis to evaluate subvisible particles during continuous drug infusion in a neonatal intensive care unit. Sci Rep. 2017;7(1):9404. https://doi.org/10.1038/s41598-017-10073-yTest; Townsley MI. Structure and composition of pulmonary arteries, capillaries and veins. Compr Physiol. 2013; 2 ( 1 ): 675 ‐ 709.; Shay DK, Fann LM, Jarvis WR. Respiratory distress and sudden death associated with receipt of a peripheral parenteral nutrition admixture, Infect Control Hosp Epidemiol. 1997; 18 ( 12 ): 814 ‐ 817.; McNearney T, Bajaj C, Boyars M, Cottingham J, Haque A. Total parenteral nutrition associated crystalline precipitates resulting in pulmonary artery occlusions and alveolar granulomas. Dig Dis Sci. 2003; 48 ( 7 ): 1352 ‐ 1354.; Reedy JS, Kuhlman JE, Voytovich M. Microvascular pulmonary emboli secondary to precipitated crystals in a patient receiving total parenteral nutrition: a case report and description of the high‐ resolution CT findings. Chest. 1999; 115 ( 3 ): 892 ‐ 895.; Melchore JA. Sound practices for consistent human visual inspection. AAPS Pharm Sci Tech. 2011; 12 ( 1 ): 215 ‐ 221.; Das T, Nema S. Protein particulate issues in biologics development. Am Pharm Rev. 2008; 11 ( 3 ): 52 ‐ 57.; Corvari V, Narhi LO, Spitznagel TM, et al. Subvisible (2‐100 μm) particle analysis during biotherapeutic drug product development: Part 2, experience with the application of subvisible particle analysis. Biologicals. 2015; 43 ( 6 ): 457 ‐ 473.; Jack T, Brent BE, Muller M, et al. Analysis of particulate contamination of infusion solutions in pediatric intensive care unit. Intensive Care Med. 2010; 36 ( 4 ): 707 ‐ 711.; Ball PA, Bethune K, Fox J, et al. Particulate contamination in parenteral nutrition solutions: still a cause for concern. Nutrition. 2001; 17: 926 ‐ 929.; Hardy G, Puzovic M. Formulation, stability, and administration of parenteral nutrition with new lipid emulsions. Nutr Clin Pract. 2009; 24 ( 5 ): 616 ‐ 25.; United States Pharmacopeia. Chapter . Globule Size Distribution in Lipid Emulsions. In: The United States Pharmacopeia, 36th rev, and the National Formulary. Rockville, MD: United States Pharmacopeia; 2019.; FDA Intralipid Alerts. Drugs.com. Accessed December 16, 2019. https://www.drugs.com/fda-alerts/1067-9297.htmlTest; Food and Drug Administration. Intralipid 20 Percent IV Fat Emulsion by Baxter: Recall ‐ One Shipment of Product Exposed to Subfreezing Temperatures. Published October 5, 2017. Accessed September 2, 2020. https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/baxter-initiates-voluntary-nationwide-recall-one-shipment-intralipid-20-iv-fat-emulsion-due-productTest; Perez M, Decaudin B, Abou Chala W, et al. In vitro analysis of overall particulate matter contamination exposure during multidrug IV therapy: Impact of infusion sets. Pediatr Blood Cancer. 2015; 62 ( 6 ): 1042 ‐ 1047.; Perez M, Decaudin B, Chahla WA, et al. Effectiveness of in‐line filters to completely remove particulate contamination during a pediatric multidrug infusion protocol. Sci Rep. 2018; 8 ( 1 ): 1 ‐ 8.; Jack T, Boehne M, Brent BE, et al. In‐line filtration reduces severe complications and length of stay on pediatric intensive care unit: A prospective, randomized, controlled trial. Intensive Care Med. 2012; 38 ( 6 ): 1008 ‐ 1016.; Benlabed M, Martin Mena A, Gaudy R,et al. Analysis of particulate exposure during continuous drug infusion in critically ill adult patients: a preliminary proof‐of‐concept in vitro study. Intensive Care Med Exp. 2018; 6 ( 1 ): 38.; Foster JP, Richards R, Showell MG, Jones LJ. Intravenous in‐line filters for preventing morbidity and mortality in neonates. Cochrane Database Syst Rev. 2015;( 8 ): CD005248.; Schmitt E, Meybohm P, Herrmann E, et al. In‐line filtration of intravenous infusion may reduce organ dysfunction of adult critical patients. Crit Care. 2019; 23: 373.; Gill M. Filtering out the Facts: Recommendations to Optimize Performance of In‐Line Filters for Parenteral Nutrition and Intravenous Fat Emulsion Infusions. BD. Published August 2019. Accessed January 27, 2020. https://www.bd.com/en-us/clinical-excellence/bd-institute-for-medication-management-excellence/blog/key-insights-from-a-recent-white-paper-on-the-performance-of-in-line-filters-for-parenteral-nutrition-and-intravenous-fat-emulsion-infusionsTest; Chau D, Gish B, Tzanetos D, Zhang C. A dangerous side of in‐line filter when used for vasoactive infusions in infants. APSF newsletter. 2013;28( 2 ):43; IV in‐line Filter FAQs. CareFusion 2010. Published 2010. Accessed October 5, 2020. https://www.bd.com/documents/faq/IF_Alaris-Pump-Module_FQ_EN.pdfTest; Newton DW. Y‐site compatibility of intravenous drugs with parenteral nutrition. JPEN J Parenter Enteral Nutr. 2013; 37 ( 3 ): 297 – 299.; Canadian Vascular Access Association. Occlusion management guideline for central vascular access devices (CVADs). J Can Vascular Access Assoc. 2013; 7 ( Suppl. 1 ): 3 – 31.; Sacks GS, Rough S, Kudsk KA. Frequency and severity of harm of medication errors related to the parenteral nutrition process in a large university teaching hospital. Pharmacotherapy. 2009; 29 ( 8 ): 966 ‐ 974.; Ayers P, Adams S, Boullata J, et al. American Society for Parenteral and Enteral Nutrition. A.S.P.E.N. Parenteral nutrition safety consensus recommendations. JPEN J Parenter Enteral Nutr. 2014; 38: 296 ‐ 333.; Boullata JI, Gilbert K, Sacks GS, et al. A.S.P.E.N. clinical guidelines: parenteral nutrition ordering, order review, compounding, labeling, and dispensing. JPEN J Parenter Enteral Nutr. 2014; 38 ( 3 ): 334 ‐ 377.; Food and Drug Administration safety alert: Hazards of precipitation associated with parenteral nutrition. Am J Hosp Pharm. 1994; 51 ( 11 ): 1427 ‐ 1428.; American Society for Parenteral and Enteral Nutrition (ASPEN). Parenteral Nutrition—New Recommendations for In‐line Filters. Accessed September 2, 2020. http://www.nutritioncare.org/News/General_News/Parenteral_Nutrition_%E2%80%93_New_Recommendations_for_In-line_FiltersTest/; Infusion Nurses Society. Infusion therapy standards of practice. J Infus Nurs. 2016; 2016 ( 1S ): S11 ‐ S159.; Cohen MR, Smetzer JL. ISMP medication error report analysis. Selected medication safety risks to manage in 2016–Part I intravenous fat emulsion needs a filter. Hosp Pharm. 2016; 51 ( 5 ): 353 ‐ 357.; ISMP Medication Safety Alert. ISMP Quarterly Action Agenda. Accessed September 2, 2020. https://www.ismp.org/sites/default/files/attachments/2018-02/ActionAgenda1602.pdfTest; Bethune K, Allwood M, Grainger C, Wormleighton C. Use of filters during the preparation and administration of parenteral nutrition: Position paper and guidelines prepared by a British pharmaceutical nutrition group working party. Nutrition. 2001; 17 ( 5 ): 403 ‐ 408.; Puntis J, Hojsak I, Ksiazyk J; ESPGHAN/ESPEN/ESPR/CSPEN working group on pediatric parenteral nutrition. ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric parenteral nutrition: organizational aspects. Clin Nutr. 2018; 37 ( 6 Pt B ): 2392 ‐ 2400.; Martindale RG, Berlana D, Boullata JI, et al. Summary of proceedings and expert consensus statements from the international summit “Lipids in Parenteral Nutrition”. JPEN J Parenter Enteral Nutr. 2020; 44 Suppl 1: S7 ‐ S20.; Christensen ML, Ayers P, Boullata JI, et al. Lipid injectable emulsion survey with gap analysis. Nutr Clin Pract. 2017; 32 ( 5 ): 694 ‐ 702.; Ball P. Intravenous in‐line filters: filtering the evidence. Currt Opin Clin Nutr. 2003; 6 ( 3 ): 319 ‐ 325.; Puntis JWL, Wilkins KM, Ball PA, Rushton DI, Booth IW. Hazards of parenteral treatment: do particles count? Arch Dis Child. 1992; 67 ( 12 ): 1475 ‐ 147; Benlabed M, Perez M, Gaudy R, et al. Clinical implications of intravenous drug incompatibilities in critically ill patients. Anesth Crit Care Pain Med. 2019; 38 ( 2 ): 173 ‐ 180.; Filtration Devices for Infusion Therapy & Drug Delivery. Pall Corporation. Published 2020. Accessed September 2, 2020. https://medical.pall.com/en/oem-manufacturing/filter-devices/liquid-filtration.htmlTest; Boehne M, Jack T, Köditz H, et al. In‐line filtration minimizes organ dysfunction: new aspects from a prospective, randomized, controlled trial. BMC Pediatr. 2013; 13: 21.; McKinnon BT. FDA safety alert: hazards of precipitation associated with parenteral nutrition. Nutr Clin Pract. 1996; 11 ( 2 ): 59 ‐ 65.; Driscoll DF, Bacon MN, Bistrian B. Effects of in‐line filtration on particle size in total nutrient admixtures. JPEN J Parenter Enteral Nutr. 1996; 20 ( 4 ): 296 ‐ 301.; Matlow AG, Kitai I, Kirpalani H, et al. A randomized trial of 72‐ versus 24‐hour intravenous tubing set changes in newborns receiving lipid therapy. Infect Control Hosp Epidemiol. 1999; 20: 487 ‐ 493.; Davis NN, Turco S, Sivelly E. Particulate matter in I.V. infusion fluids. Bull Parenter Drug Assoc. 1970; 24(6): 257 ‐ 270.; Davis NM, Turco S, Sivelly E. A study of particulate matter in I.V. infusion fluids. Am J Hosp Pharm. 1970; 27 ( 10 ): 822 ‐ 826.; Davis NM, Turco S. A study of particulate matter in I.V. Infusion fluids—Phase 2. Am J Hosp Pharm. 1971; 28 ( 8 ): 620 ‐ 623.; Turco SJ, Davis NM. Particulate matter in intravenous infusion fluids—Phase 3. Am J Hosp Pharm. 1973; 30 ( 7 ): 611 ‐ 613.; Hill SE, Heldman LS, Goo ED, Whippo PE, Perkinson JC. Fatal microvascular pulmonary emboli from precipitation of a total nutrient admixture solution. JPEN J Parenter Enteral Nutr. 1996; 20 ( 1 ): 81 ‐ 87.; Knowles, JB, et al, Pulmonary deposition of calcium phosphate crystals as a complication of home total parenteral nutrition. JPEN J Parenter Enteral Nutr. 1989; 13 ( 2 ): 209 – 213.; Robinson LA, Wright BT. Central venous catheter occlusion caused by body‐heat‐mediated calcium phosphate precipitation. Am J Hosp Pharm. 1982; 39 ( 1 ): 120 ‐ 121.; Breaux CW Jr, Duke D, Georgeson KE, Mestre JR. Calcium phosphate crystal occlusion of central venous catheters used for total parenteral nutrition in infants and children: prevention and treatment. J Pediatr Surg. 1987; 22 ( 9 ): 829 – 832.; Maki DG, Goldman Dam Rhame FS. Infection control in intravenous therapy. Ann Intern Med. 1973; 79 ( 6 ): 867 ‐ 887.; Wilmore DW, Dudrick SJ. An in‐line filter for venous solutions. Arch Surg. 1969; 99 ( 4 ): 462 ‐ 463.; Jornitz MW, Akers, JE, Agalloco JP, Madsen RE, Meltzer TH. Considerations in sterile filtration. Part II: the sterilizing filter and its organism challenge: a critique of regulatory standards. PDA J Pharm Sci Technol. 2003; 57 ( 2 ): 88 ‐ 96.; O’Grady NP, Dellinger EP, Gerberding JL, et al. Guidelines for the prevention of intravascular‐catheter related infections. Morb Mortal Wkly Rep (MMWR). 2002; 51 ( RR‐10 ): 1 ‐ 29.; Oie S, Kamiya A. Particulate and microbial contamination in in‐use admixed parenteral nutrition solutions. Biol Pharm Bull. 2005; 28 ( 12 ): 2268 ‐ 2270.; O’Grady NP, Alexander M, Burns LA, et al. Guidelines for the prevention of intravascular catheter‐related infection. Clin Infect Dis. 2011; 52 ( 9 ): e162 ‐ e193.; United States Pharmacopeia. Pharmaceutical compounding—sterile preparations (Chapter 797). In: The United States Pharmacopeia, 36th rev, and the National Formulary. Rockville, MD: The United States Pharmacopeial Convention; 2008.; Mirtallo J, Canada T, Johnson D, et al. Safe practices for parenteral nutrition. JPEN J Parenter Enteral Nutr. 2004; 28 ( 6 ): S39 ‐ S69.; Hirsch A. In line filters and injectable lipid emulsions. GASPEN Newsletter. 2019;(5): 6 ‐ 9.; Intralipid 20%. Package insert. Fresenius Kabi; 2015.; Nutrilipid. Package insert. B. Braun Medical Inc; 2017.; Clinolipid. Package insert. Baxter Healthcare Corporation; 2016.; SMOFlipid. Package insert. Fresenius Kabi; 2015.; Omegaven. Package insert. Fresenius Kabi; 2018.; VA Comprehensive Pharmacovigilance Center. Intralipid IV fat emulsion products in Biofine containers: particulate matter observed. Medication Safety Seconds. 2016; 6 ( 1 ): 3.; United States Pharmacopeia. Chapter Particulate Matter in Injections. USP 35. In: The United States Pharmacopeia, 36th rev, and the National Formulary. Rockville, MD: US Pharmacopeial Convention; 2013.; Tran T, Kupiec TC, Trissel LA. Particulate matter in injections: what is it and what are the concerns. Int J Pharm Compounding. 2006; 10 ( 3 ): 202 ‐ 204; Langille SE. Particulate matter in injectable drug products. PDA J Pharm Sci Tech. 2013; 67 ( 3 ): 186 ‐ 200.; Perez M, Maiguy‐Foinard A, Barthelemy C, Decaudin B, Odou P. Particulate matter in injectable drugs: evaluation to risks to patients. Pharm Technol Hosp Pharm. 2016; 1 ( 2 ): 91 ‐ 103.; Gordon S. Sacks, filtration of parenteral nutrition admixtures: friend or foe. Nutrition. 1997; 13 ( 10 ): 936 ‐ 937.; Newton DW, Driscoll DF. Calcium and phosphate compatibility: revisited again. Am J Health Syst Pharm. 2008; 65 ( 1 ): 73 ‐ 80.

  7. 7
    دورية أكاديمية
  8. 8
    دورية أكاديمية
  9. 9
    دورية أكاديمية

    المصدر: Nutrition in Clinical Practice ; volume 20, issue 5, page 579-590 ; ISSN 0884-5336 1941-2452

  10. 10
    دورية أكاديمية

    المصدر: Nutrition in Clinical Practice ; volume 34, issue 2, page 216-219 ; ISSN 0884-5336 1941-2452